par Bosiers, M;Deloose, K;Callaert, Julie;Maene, L;Beelen, R;Keirse, Marc M.J.N.C.;Verbist, J.;Peeters, P;Schroë, H;Lauwers, G;Lansink, W;Vanslembroeck, K;D'archambeau, O;Hendriks, John 
;Lauwers, P;Vermassen, Frank;Randon, Caren;Van Herzeele, I;De Ryck, Frederic F.D.;De Letter, J;Lanckneus, M;Van Betsbrugge, M;Thomas, B;Deleersnijder, R;Vandekerkhof, J;Baeyens, I;Berghmans, Thierry ;Buttiens, J;Van Den Brande, Paul;Debing, Erik;Rabbia, C;Ruffino, A;Tealdi, D;Nano, G;Stegher, S;Gasparini, D;Piccoli, G;Coppieters De Gibson, Arnold G. ;Silingardi, R;Cataldi, V;Paroni, G;Palazzo, V;Stella, A;Gargiulo, Miriam;Muccini, N;Nessi, F;Ferrero, E;Pratesi, C;Fargion, A;Chiesa, R;Marone, E;Bertoglio, L;Cremonesi, A;Dozza, L;Galzerano, G;De Donato, G;Setacci, C.
Référence Journal of Cardiovascular Surgery, 54, 2, page (235-253)
Publication Publié, 2013-04
;Lauwers, P;Vermassen, Frank;Randon, Caren;Van Herzeele, I;De Ryck, Frederic F.D.;De Letter, J;Lanckneus, M;Van Betsbrugge, M;Thomas, B;Deleersnijder, R;Vandekerkhof, J;Baeyens, I;Berghmans, Thierry ;Buttiens, J;Van Den Brande, Paul;Debing, Erik;Rabbia, C;Ruffino, A;Tealdi, D;Nano, G;Stegher, S;Gasparini, D;Piccoli, G;Coppieters De Gibson, Arnold G. ;Silingardi, R;Cataldi, V;Paroni, G;Palazzo, V;Stella, A;Gargiulo, Miriam;Muccini, N;Nessi, F;Ferrero, E;Pratesi, C;Fargion, A;Chiesa, R;Marone, E;Bertoglio, L;Cremonesi, A;Dozza, L;Galzerano, G;De Donato, G;Setacci, C.Référence Journal of Cardiovascular Surgery, 54, 2, page (235-253)
Publication Publié, 2013-04
Article révisé par les pairs
| Résumé : | The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery. |
